| Document Date: 2015-01-08 10:33:54
Open Document File Size: 924,74 KBShare Result on Facebook
Company Introduction Page 5 Pharmaceutical / Novartis Pharmaceuticals UK Ltd / / Country United Kingdom / / Currency pence / / Event FDA Phase / / Facility Artemether INN / Lumefantrine INN / / IndustryTerm pharmaceutical form / pharmaceutical aspects / healthcare professionals / pharmaceutical excipients / reference product / manufacturing method / treatment of malaria / patients/healthcare professionals / test product / medicinal product / Suitable pharmaceutical development data / food vacuole / food / manufacturing process / / MedicalCondition blisters / headache / stomach pain / malaria / muscle ache / nausea / vomiting / severe malaria / acute uncomplicated Plasmodium falciparum malaria / infection / malaria infections / dizziness / cough / tiredness / / Organization European Medicines Agency / MHRA PAR / MHRA / US Federal Reserve / European Union / European Parliament / / Position pharmacist / / Product MG/120 MG DISPERSIBLE TABLETS / Riamet 20mg/120mg / Riamet tablet / dispersible / Riamet / / ProgrammingLanguage EC / / Technology PHARMACOKINETICS / PHARMACODYNAMICS / /
SocialTag |
RIAMET 20 MG/120 MG DISPERSIBLE TABLETS (Artemether and lumefantrine) PL[removed]UKPAR